Monoclonal Antibodies for Ebola and Marburg Viruses

Abstract

Described herein are a number of Ebola and Marburg monoclonal antibodies.

1 - 4 . (canceled) 
     
     
         5 . A pharmaceutical composition for the treatment of Ebola, the pharmaceutical composition comprising at least a first monoclonal antibody and a second monoclonal antibody, wherein the first monoclonal antibody is selected from a group consisting of:
 (a) a monoclonal antibody or antigen binding fragment thereof comprising a light chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 2, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said light chain variable region have been changed or deleted; and a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No: 1, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said heavy chain variable region have been changed or deleted;   (b) a monoclonal antibody or antigen binding fragment thereof comprising a light chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 4, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said light chain variable region have been changed or deleted; and a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No: 3, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said heavy chain variable region have been changed or delete& and   (c) a monoclonal antibody or antigen binding fragment thereof comprising a light chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO:6, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said light chain variable region have been changed or deleted; and a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No: 5, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said heavy chain variable region have been changed or deleted.   
     
     
         6 . The pharmaceutical composition of  claim 5 , further comprising a pharmaceutically acceptable excipient or carrier. 
     
     
         7 . A method of treating a patient suspected of having hemorrhagic fever or at risk of developing hemorrhagic fever, the method comprising:
 i) identifying such a patient   ii) administering a therapeutically effective amount of a pharmaceutical composition comprising at least a first monoclonal antibody and a second monoclonal antibody, wherein the first monoclonal antibody is selected from a group consisting of:   (a) a monoclonal antibody or antigen binding fragment thereof comprising a light chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 2, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said light chain variable region have been changed or deleted and a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No: 1, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said heavy chain variable region have been changed or deleted;   (b) a monoclonal antibody or antigen binding fragment thereof comprising a light chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 4, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said light chain variable region have been changed or deleted and a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No: 3, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said heavy chain variable region have been changed or deleted; and   (c) a monoclonal antibody or antigen binding fragment thereof comprising a light chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO: 6, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said light chain variable region have been changed or deleted and a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No: 5, or variants thereof whereby at least one but fewer than 30 of the amino acid residues of said heavy chain variable region have been changed or deleted.   
     
     
         8 . The method of  claim 7 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient or carrier.